Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. develops clinical-stage cell therapy and small-molecule product candidates for cancer and related disease areas. News about TPST centers on its dual-targeting CAR-T platform, including TPST-2003, a CD19/BCMA CAR-T therapy under development for relapsed or refractory multiple myeloma, and clinical updates from programs such as REDEEM-1 and POEMS-1.
Company updates also cover CAR-T manufacturing and technology-transfer work, partner-supported development activities, business development and licensing priorities, and the amezalpat small-molecule program. Recurring corporate news includes financial results, pipeline portfolio changes following acquired CAR-T assets, leadership appointments, and governance or capital-structure matters tied to the company’s Nasdaq-listed common stock.
Tempest Therapeutics (Nasdaq: TPST) presented new data on TPST-1120 and TPST-1495 at the SITC Annual Meeting in Boston (Nov 10-12, 2022). TPST-1120, a PPAR-α antagonist, showed promising pharmacodynamic changes in patients who benefited from treatment. Meanwhile, TPST-1495 demonstrated superior immune activation compared to single inhibitors and reduced tumor size in preclinical models. The findings suggest potential biomarkers for patient selection in future studies, strengthening the company's position in oncology therapeutics.
Tempest Therapeutics, Inc. (Nasdaq: TPST) reported its Q3 2022 financial results, highlighting a net loss of $8.9 million or $0.66 per share, compared to a net loss of $8.1 million or $1.21 per share in Q3 2021. The company ended the quarter with $42.8 million in cash, down from $51.8 million at year-end 2021. Research and development expenses increased to $6.0 million, driven by expanded efforts. Tempest continues enrollment in clinical trials for its products TPST-1120 and TPST-1495, with key data presentations expected at the upcoming SITC annual meeting.
Tempest Therapeutics, Inc. (TPST) announced the acceptance of two poster presentations, including a late-breaking presentation of its oral selective PPAR⍺ antagonist, TPST-1120, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting from November 10-12, 2022, in Boston, MA. The late-breaking presentation focuses on pharmacodynamic and predictive biomarkers in patients treated with TPST-1120, while the second presentation discusses dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495.
Tempest Therapeutics, a clinical-stage oncology company, announced participation in the Emerging Technologies for IO Targeting and Discovery Summit on October 13-14, 2022. Dara Burdette, Ph.D., will chair a session on 'New Approaches to Solid Tumor Targeting' and present on the TREX1 pipeline asset. Additionally, Nicholas DeVito, M.D., will share preclinical data on TPST-1495, a dual inhibitor targeting EP2 and EP4 receptors. Both presentations aim to enhance understanding of tumor-targeted therapies and immune response.
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company, announced that CEO Stephen R. Brady will present at the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. ET on the Tempest investor website. The company is focused on developing innovative therapeutics, including its lead candidates, TPST-1120 and TPST-1495, which target various tumor mechanisms. More details can be found on the company's website.
Tempest Therapeutics (Nasdaq: TPST) reported its Q2 2022 financial results, showing a net loss of $9.2 million and a net loss per share of $0.79, compared to a net loss of $7.1 million and $7.63 per share in Q2 2021. Cash and cash equivalents stood at $51.6 million, slightly down from $51.8 million at the end of 2021. The company successfully closed a $15 million PIPE financing, extending its financial runway into 2024. Key developments included progress on clinical studies for TPST-1120 and TPST-1495, with expected data releases by early 2023.
Tempest Therapeutics (Nasdaq: TPST) announced that President Tom Dubensky, Ph.D. will participate in a panel on Next Generation Immuno-Oncology Targets at the 2022 William Blair Biotech Focus Conference on July 12, 2022, at 4:10 p.m. ET. The company, based in South San Francisco, focuses on developing first-in-class therapeutics that integrate targeted and immune-mediated mechanisms for treating various tumors. Key clinical programs include TPST-1120 and TPST-1495, advancing through trials as monotherapies and in combination treatments.
Tempest Therapeutics (TPST) presented promising results from its TPST-1120 clinical program at the 2022 ASCO Annual Meeting. The drug demonstrated clinical benefits in patients with late-line advanced cancers, showing a 53% clinical benefit rate when used as monotherapy. In combination with anti-PD-1 therapy, it provided objective responses in patients previously resistant to such treatments. A potential biomarker for patient responsiveness was identified. Additionally, the company expects sufficient cash runway into the first quarter of 2024 to support ongoing studies.
Tempest Therapeutics (Nasdaq: TPST) announced its participation at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 a.m. ET. The company, focused on innovative oncology therapeutics, is advancing clinical programs TPST-1120 and TPST-1495 that target tumors through both targeted and immune-mediated mechanisms. TPST-1120 is undergoing a Phase 1b/2 study in collaboration with Roche for treating advanced hepatocellular carcinoma. For access to the presentation, visit Tempest's investor section online.
Tempest Therapeutics, Inc. (TPST) reported promising Phase 1 clinical trial results for its novel therapy, TPST-1120, both as a monotherapy and in combination with nivolumab. The data highlighted a 30% Objective Response Rate (ORR) at higher doses of TPST-1120 combined with nivolumab and a 53% Disease Control Rate (DCR) for patients on TPST-1120 alone. Notably, patients with advanced renal cell carcinoma showed a 50% ORR. The product displayed a favorable safety profile, with no severe toxicities reported. Continued development is expected, with results to be shared at the upcoming ASCO Annual Meeting.